Elissa Meites, Carol Lin, Elizabeth R. Unger, Martin Steinau, Sonya Patel, Lauri E. Markowitz and Susan Hariri Can clinical tests help monitor human papillomavirus vaccine impact? International Journal of Cancer 133
The impact of human papillomavirus (HPV) immunization on cervical cancer incidence in populations of vaccinated women may not be apparent for decades, complicating evaluation of the early effectiveness of HPV vaccination programs. Evidence presented here indicates that it may be possible to do this by performing HPV-type analysis on cervical specimens, since one of the earliest measurable effects of HPV vaccine in a population should be a reduction in specific HPV types. The triage of cervical specimens for HPV typing based on results of a clinical HPV test such as the digene hybrid capture 2 (HC-2) could complement existing cervical cancer screening programs and reduce overall testing costs, and therefore may be appealing for use in low-resource settings.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf